EP3600430A4 - Folate conjugate for use in targeting tumor associated macrophages - Google Patents

Folate conjugate for use in targeting tumor associated macrophages Download PDF

Info

Publication number: EP3600430A4
Authority: EP; European Patent Office
Prior art keywords: tumor associated; associated macrophages; targeting tumor; folate conjugate; folate
Prior art date: 2016-03-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17903862.5A

Other languages

German (de)

French (fr)

Other versions

EP3600430A1 (en

Inventor

Iontcho Radoslavov Vlahov

Christopher Paul Leamon

Longwu Qi

Ning Zou

Kevin Yu Wang

Albert E. FELTEN

Garth L. Parham

Fei You

Hari Krishna R. Santhapuram

Spencer J. HAHN

Joseph Anand Reddy

Yingjuan J. LU

II Leroy W. WHEELER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Endocyte Inc

Original Assignee

Endocyte Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-29

Filing date

2017-09-14

Publication date

2020-12-30

2017-03-29 Priority claimed from PCT/US2017/024770 external-priority patent/WO2017172930A1/en

2017-09-14 Application filed by Endocyte Inc filed Critical Endocyte Inc

2020-02-05 Publication of EP3600430A1 publication Critical patent/EP3600430A1/en

2020-12-30 Publication of EP3600430A4 publication Critical patent/EP3600430A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP17903862.5A 2016-03-29 2017-09-14 Folate conjugate for use in targeting tumor associated macrophages Withdrawn EP3600430A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662314688P	2016-03-29	2016-03-29
US201662323282P	2016-04-15	2016-04-15
US201662396409P	2016-09-19	2016-09-19
PCT/US2017/024770 WO2017172930A1 (en)	2016-03-29	2017-03-29	Pbd conjugates for treating diseases
PCT/US2017/051662 WO2018182776A1 (en)	2016-03-29	2017-09-14	Folate conjugate for use in targeting tumor associated macrophages

Publications (2)

Publication Number	Publication Date
EP3600430A1 EP3600430A1 (en)	2020-02-05
EP3600430A4 true EP3600430A4 (en)	2020-12-30

Family

ID=69140942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17903862.5A Withdrawn EP3600430A4 (en)	2016-03-29	2017-09-14	Folate conjugate for use in targeting tumor associated macrophages

Country Status (3)

Country	Link
EP (1)	EP3600430A4 (en)
CN (1)	CN110678204A (en)
WO (1)	WO2018182776A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112791192B (en) *	2020-12-31	2023-04-07	上海交通大学	Inflammatory cell targeted melittin liposome nano preparation and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014062697A2 (en) *	2012-10-16	2014-04-24	Endocyte, Inc.	Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016085967A1 (en) *	2014-11-25	2016-06-02	Endocyte, Inc.	Methods of treating cancer by targeting tumor-associated macrophages
WO2017172930A1 (en) *	2016-03-29	2017-10-05	Endocyte, Inc.	Pbd conjugates for treating diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1592457B1 (en) *	2003-01-27	2012-07-25	Endocyte, Inc.	Folate-vinblastine conjugate as medicament
CN104383553A (en) *	2007-06-25	2015-03-04	恩多塞特公司	Conjugates containing hydrophilic spacer linkers
CA2737496A1 (en) *	2008-09-17	2010-03-25	Endocyte, Inc.	Folate receptor binding conjugates of antifolates
AU2010278734A1 (en) *	2009-07-31	2012-02-23	Endocyte, Inc.	Folate-targeted diagnostics and treatment

2017
- 2017-09-14 CN CN201780091404.8A patent/CN110678204A/en active Pending
- 2017-09-14 WO PCT/US2017/051662 patent/WO2018182776A1/en not_active Ceased
- 2017-09-14 EP EP17903862.5A patent/EP3600430A4/en not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014062697A2 (en) *	2012-10-16	2014-04-24	Endocyte, Inc.	Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016085967A1 (en) *	2014-11-25	2016-06-02	Endocyte, Inc.	Methods of treating cancer by targeting tumor-associated macrophages
WO2017172930A1 (en) *	2016-03-29	2017-10-05	Endocyte, Inc.	Pbd conjugates for treating diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON ET AL: "Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship", BIOCONJUGATE CHEMISTRY, vol. 25, no. 3, 19 March 2014 (2014-03-19), pages 560 - 568, XP055749294, ISSN: 1043-1802, DOI: 10.1021/bc400441s *
JOSEPH A. REDDY ET AL: "Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent", SCIENTIFIC REPORTS, vol. 10, no. 1, 29 July 2020 (2020-07-29), XP055749599, DOI: 10.1038/s41598-020-69682-9 *
See also references of WO2018182776A1 *
YINGJUAN LU ET AL: "Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus", MOLECULAR MEDICINE, vol. 21, no. 1, 1 January 2015 (2015-01-01), WASHINGTON, DC; US, pages 584 - 596, XP055749288, ISSN: 1076-1551, DOI: 10.2119/molmed.2015.00040 *

Also Published As

Publication number	Publication date
CN110678204A (en)	2020-01-10
EP3600430A1 (en)	2020-02-05
WO2018182776A1 (en)	2018-10-04

Publication	Publication Date	Title
IL265919B (en)	2020-06-30	Pyrrolobenzodiazepine conjugates
EP3107557A4 (en)	2017-11-01	Hydrophilic antibody-drug conjugates
ZA201805526B (en)	2019-05-29	Pyrrolobenzodiazepine conjugates
GB201607478D0 (en)	2016-06-15	Pyrrolobenzodiazepine Conjugates
EP3501548A4 (en)	2020-06-17	Tissue factor-targeted antibody-drug conjugate
IL272625B1 (en)	2023-04-01	Pyrrolobenzodiazepine conjugates
EP3207162A4 (en)	2018-07-04	Combination therapy for use in cancer therapy
IL269945B (en)	2021-05-31	Pyrrolobenzodiazepine conjugates
GB201602359D0 (en)	2016-03-23	Pyrrolobenzodiazepine Conjugates
EP3261678B8 (en)	2021-03-17	Antibody-urease conjugates for therapeutic purposes
GB201602363D0 (en)	2016-03-23	Pyrrolobenzodiazepine conjugates
EP3267975A4 (en)	2018-08-08	Polymer-drug conjugates for combination anticancer therapy
GB201619490D0 (en)	2017-01-04	Pyrrolobenzodiazepine conjugates
HUE052670T2 (en)	2021-05-28	Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
EP3600430A4 (en)	2020-12-30	Folate conjugate for use in targeting tumor associated macrophages
HK40023923A (en)	2020-12-04	Folate conjugate for use in targeting tumor associated macrophages
EP3665302A4 (en)	2021-04-28	Drug combinations for targeting multiple mutations in cancer
HK40117905A (en)	2025-05-30	Antibody-urease conjugates for therapeutic purposes
GB201721337D0 (en)	2018-01-31	Pyrrolobenzodiazepine conjugates
GB201706133D0 (en)	2017-05-31	Pyrrolobenzodiazepine conjugates
HK1237824A1 (en)	2018-04-20	Combination therapy for use in cancer therapy
GB201607485D0 (en)	2016-06-15	Pyrrolobenzodiazepine Conjugates
GB201607488D0 (en)	2016-06-15	Pyrrolobenzodiazepine Conjugates
GB201602360D0 (en)	2016-03-23	Pyrrolobenzodiazepine conjugates
HK1236836A1 (en)	2018-04-06	Conjugates comprising cell-binding agents and cytotoxic agents

Legal Events

Date	Code	Title	Description
2018-10-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-01-03	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-01-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-02-05	17P	Request for examination filed	Effective date: 20191025
2020-02-05	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-02-05	AX	Request for extension of the european patent	Extension state: BA ME
2020-03-18	RIN1	Information on inventor provided before grant (corrected)	Inventor name: LEAMON, CHRISTOPHER PAUL Inventor name: WANG, KEVIN YU Inventor name: ZOU, NING Inventor name: FELTEN, ALBERT E. Inventor name: QI, LONGWU Inventor name: PARHAM, GARTH L. Inventor name: REDDY, JOSEPH ANAND Inventor name: YOU, FEI Inventor name: VLAHOV, IONTCHO RADOSLAVOV Inventor name: HAHN, SPENCER J. Inventor name: WHEELER, II, LEROY W. Inventor name: LU, YINGJUAN J. Inventor name: SANTHAPURAM, HARI KRISHNA R.
2020-05-27	RIN1	Information on inventor provided before grant (corrected)	Inventor name: FELTEN, ALBERT E. Inventor name: PARHAM, GARTH L. Inventor name: WHEELER, II, LEROY W. Inventor name: LU, YINGJUAN J. Inventor name: WANG, KEVIN YU Inventor name: SANTHAPURAM, HARI KRISHNA R. Inventor name: HAHN, SPENCER J. Inventor name: VLAHOV, IONTCHO RADOSLAVOV Inventor name: ZOU, NING Inventor name: LEAMON, CHRISTOPHER PAUL Inventor name: QI, LONGWU Inventor name: YOU, FEI Inventor name: REDDY, JOSEPH ANAND
2020-07-08	DAV	Request for validation of the european patent (deleted)
2020-07-08	DAX	Request for extension of the european patent (deleted)
2020-12-04	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40023923 Country of ref document: HK
2020-12-30	A4	Supplementary search report drawn up and despatched	Effective date: 20201130
2020-12-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 47/55 20170101AFI20201124BHEP Ipc: A61P 35/00 20060101ALI20201124BHEP
2021-11-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-12-08	18D	Application deemed to be withdrawn	Effective date: 20210629